Adverse effects of biologics: a network meta-analysis and Cochrane overview-Reference-Cited by-同舟云学术

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Published:2011-02-16 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Singh Jasvinder A¹,Wells George A²,Christensen Robin³,Tanjong Ghogomu Elizabeth⁴,Maxwell Lara J⁵,MacDonald John K⁶,Filippini Graziella⁷,Skoetz Nicole⁸,Francis Damian K⁹,Lopes Luciane C¹⁰,Guyatt Gordon H¹¹,Schmitt Jochen¹²,La Mantia Loredana¹³,Weberschock Tobias¹⁴¹⁵,Roos Juliana F¹⁶,Siebert Hendrik¹⁷,Hershan Sarah¹⁸,Cameron Chris²,Lunn Michael PT¹⁹,Tugwell Peter²⁰²¹²²,Buchbinder Rachelle²³

Affiliation:

1. Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham AL USA 35294

2. University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7

3. Copenhagen University Hospital, Bispebjerg og Frederiksberg; Musculoskeletal Statistics Unit, The Parker Institute; Nordre Fasanvej 57 Copenhagen Denmark DK-2000

4. University of Ottawa; Bruyère Research Institute; 43 Bruyère St Annex E, room 302 Ottawa ON Canada K1N 5C8

5. Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus; Centre for Practice-Changing Research (CPCR); 501 Smyth Road, Box 711 Ottawa ON Canada K1H 8L6

6. Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6

7. Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Scientific Direction; via Celoria, 11 Milano Italy 20133

8. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937

9. University of West Indies; Epidemiology Research Unit; Mona Kingston 7 Jamaica

10. University of Sorocaba, São Paulo; Sciences of Pharmaceutical Program; Rodovia Raposo Tavares, s/n Sorocaba São Paulo Brazil CEP 18023-000

11. McMaster University; Department of Clinical Epidemiology and Biostatistics; 1200 Main Street West Hamilton ON Canada L8N 3Z5

12. Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden; Center for Evidence-Based Healthcare; Fetscherstr. 74 Dresden Germany 01307

13. I.R.C.C.S. Santa Maria Nascente - Fondazione Don Gnocchi; Unit of Neurorehabilitation - Multiple Sclerosis Center; Via Capecelatro, 66 Milano Italy 20148

14. Goethe University; Evidence-Based Medicine Frankfurt, Institute of General Practice; Theodor Stern Kai 7 Frankfurt Germany 60590

15. J.W. Goethe-University Hospital; Department of Dermatology, Venereology, and Allergology; Theodor-Stern-Kai 7 Frankfurt Germany 60590

16. Dubai Pharmacy College; Dept of Clinical Pharmacy & Pharmacy Practice; Po Box 19099 AlMuhaisanah 1, Al mizhar Dubai United Arab Emirates

17. University Hospital Cologne; Cochrane Haematological Malignancies Group; Kerpener Strasse 62 Cologne Germany 50924

18. Department of Epidemiology and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology at Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144

19. National Hospital for Neurology and Neurosurgery; Department of Neurology and MRC Centre for Neuromuscular Diseases; Queen Square London UK WC1N 3BG

20. Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5

21. Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa ON Canada K1Y 4E9

22. Faculty of Medicine, University of Ottawa; Department of Epidemiology and Community Medicine; Ottawa ON Canada K1H 8M5

23. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD008794.pub2/fullpdf

Reference290 articles.

1. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis;Abe;Journal of Rheumatology,2006

2. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial;Antoni;Annals of the Rheumatic Diseases,2005

3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[Erratum appears in Arthritis Rheum. 2005 Sep;52(9):2951];Antoni;Arthritis and Rheumatism,2005

4. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT);Antoni;Journal of Rheumatology,2008

5. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial;Aviles;Cancer Biotherapy and Radiopharmaceuticals,2007

Cited by 603 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study;Expert Opinion on Drug Safety;2024-08-30

2. Targeted therapies and conventional care for the treatment of ankylosing spondylitis in China: a cost-effectiveness analysis based on the network-meta analysis;Journal of Orthopaedic Surgery and Research;2024-08-18

3. Intra-Articular Delivery of an AAV-Anti-TNF-α Vector Alleviates the Progress of Arthritis in a RA Mouse Model;Human Gene Therapy;2024-08-12

4. Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models;American Journal of Physiology-Gastrointestinal and Liver Physiology;2024-08-01

5. Therapeutic Potential of Nanocarriers in the Management of Rheumatoid Arthritis;Current Rheumatology Reviews;2024-07-30